KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Total Debt (2016 - 2020)

Historic Total Debt for Neogenomics (NEO) over the last 12 years, with Q1 2020 value amounting to $95.6 million.

  • Neogenomics' Total Debt rose 185.05% to $95.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was $95.6 million, marking a year-over-year increase of 185.05%. This contributed to the annual value of $96.8 million for FY2019, which is 112.37% up from last year.
  • Neogenomics' Total Debt amounted to $95.6 million in Q1 2020, which was up 185.05% from $96.8 million recorded in Q4 2019.
  • Neogenomics' Total Debt's 5-year high stood at $99.3 million during Q3 2019, with a 5-year trough of $52.8 million in Q3 2016.
  • For the 5-year period, Neogenomics' Total Debt averaged around $80.6 million, with its median value being $78.2 million (2017).
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 4778.69% in 2017, then crashed by 1121.53% in 2018.
  • Quarter analysis of 5 years shows Neogenomics' Total Debt stood at $73.9 million in 2016, then dropped by 4.78% to $70.4 million in 2017, then surged by 36.08% to $95.8 million in 2018, then grew by 1.12% to $96.8 million in 2019, then fell by 1.26% to $95.6 million in 2020.
  • Its Total Debt was $95.6 million in Q1 2020, compared to $96.8 million in Q4 2019 and $99.3 million in Q3 2019.